Researchers on the Icahn School of Medicine at Mount Sinai have made a significant breakthrough in Alzheimer’s research by finding a brand new approach to potentially slow and even stop the progression of the disease. The study, which focuses on the role of reactive astrocytes and the protein Plexin-B1 within the pathophysiology of Alzheimer’s disease, provides crucial insights into how brain cells communicate and opens the door to progressive treatment strategies. It was published May 27 in (DOI 10.1038/s41593-024-01664-w).
At the guts of this groundbreaking work is manipulating the protein Plexin-B1 to enhance the brain’s ability to clear amyloid plaques, an indicator of Alzheimer’s disease. Reactive astrocytes, a variety of brain cell that’s activated in response to injury or disease, were found to play a critical role on this process. They assist control the spacing around amyloid plaques and influence how other brain cells can reach and clear these harmful deposits.
Our findings offer a promising approach for developing recent treatments by improving the interaction of cells with these harmful plaques.”
Roland Friedel, PhD, associate professor of neuroscience and neurosurgery at Icahn Mount Sinai and lead writer of the study
The research was based on the evaluation of complex data comparing healthy individuals with Alzheimer’s patients. The aim was to grasp the molecular and cellular basis of the disease.
Hongyan Zou, PhD, professor of neurosurgery and neuroscience at Icahn Mount Sinai and one in every of the study’s lead authors, highlighted the broader implications of their findings: “
One in every of the study’s most important achievements is the validation of multiscale gene network models of Alzheimer’s disease. “This study not only confirms one in every of the important thing predictions of our gene network models, but additionally significantly advances our understanding of Alzheimer’s disease. It lays a solid foundation for the event of novel therapeutics targeting such highly predictive network models,” said Bin Zhang, PhD, Willard TC Johnson Research Professor of Neurogenetics at Icahn Mount Sinai and one in every of the study’s lead authors. By demonstrating the critical role of Plexin-B1 in Alzheimer’s disease, the research highlights the potential of targeted therapies to interrupt disease progression.
The research team emphasizes that while their findings represent a major advance within the fight against Alzheimer’s, further research is required to translate these findings into treatments for human patients.
,” added Dr. Zhang, emphasizing the team’s commitment to further explore the therapeutic potential of Plexin-B1.
This study is supported by grants U01AG046170 and RF1AG057440 from the NIH National Institute on Aging (NIA) and is an element of the NIA-led Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD) Goal Discovery and Preclinical Validation program. This public-private partnership goals to shorten the time between the invention of potential drug targets and the event of recent drugs to treat and forestall Alzheimer’s disease.
The title of the paper is “Regulation of cell distancing in periplaque glial networks by Plexin-B1 influences glial activation and amyloid compaction in Alzheimer’s disease.”
Source:
Journal reference:
Huang, Y., . (2024). Regulation of cell distancing in periplaque glial networks by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer’s disease. . doi.org/10.1038/s41593-024-01664-w.
